Physician profile
Bashar Al Jayyousi
NPI 1225292568
$7,066.10
in general payments reported to CMS, 2019-2025
42 companies · $524 in 2025
The $524 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,698 · 2020: $311 · 2021: $596 · 2022: $1,375 · 2023: $1,208 · 2024: $354 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Travel and Lodging: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.46 |
| Travel and Lodging | $267.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,552.56 | 2021-2023 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $1,487.09 | 2019-2023 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $397.71 | 2019-2025 | |
| Shockwave Medical, INC | $376.82 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $323.80 | 2019-2025 | |
| Abbott Laboratories | $304.96 | 2021-2023 | Optis |
| Astellas Pharma US INC | $295.03 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $258.85 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $229.00 | 2019-2025 | Eliquis |
| Medtronic, INC. | $214.25 | 2021-2024 | Corevalve Evolut R |
| Novo Nordisk INC | $210.99 | 2024-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.25 | 2019-2022 | |
| Amgen INC. | $118.13 | 2019-2023 | Repatha |
| Abiomed | $115.55 | 2023 | Impella |
| Philips North America LLC | $100.43 | 2023-2025 | Igt Devices Undivided |
Show all 40 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Al Jayyousi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.